Roche's Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA's Accelerated Approval for Relapsed/Refractory Lymphoma
Shots:
- The accelerated approval is based on P-Ib/II GO29365 study results involves assessing of Polivy + bendamustine + Rituxan (BR)/Gazyva (obinutuzumab) vs BR in patients with r/r follicular lymphoma or DLBCL with 2L+ treatment
- The P-Ib/II GO29365 study results: CRR (40% vs 18%); objective response (45% vs 18%); DOR lasting at least 6mos. (64% vs 30%); DOR lasting at least a year (48% vs 20%)
- Polivy is an anti-CD79b anti-body drug conjugate and has received FDA’s PR designation in Feb’19 with FDA’s BT & EMA’s PRIME designation in 2017 for r/r DLBCL
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com